Brief: Calliditas Therapeutics Preliminary 2023 Total Revenues At $110-113 Mln
08/01/2024 08:28
Jan 8 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* Q4 PRELIMINARY PRODUCT REVENUE GROWTH WITH NET TARPEYO
REVENUES
OF $31 - 33M
* PRELIMINARY TOTAL REVENUES REACHING $110 - 113M FOR 2023,
AS A
RESULT OF MILESTONE PAYMENTS AND ROYALTY INCOME
Source text for Eikon: ID:nWkr1vqSVP
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations